Mark Hopman - 04 Sep 2025 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Signature
/s/ Stephen Feider, Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
04 Sep 2025
Net transactions value
-$288,421
Form type
4
Filing time
08 Sep 2025, 18:15:07 UTC
Previous filing
04 Sep 2025
Next filing
13 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopman Mark Chief Commercial Officer C/O BETA BIONICS, INC., 11 HUGHES, IRVINE /s/ Stephen Feider, Attorney-in-Fact 08 Sep 2025 0002048497

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBNX Common Stock Options Exercise $3,346 +656 +2% $5.10 33,940 04 Sep 2025 Direct
transaction BBNX Common Stock Options Exercise $20,874 +4,093 +12% $5.10 38,033 04 Sep 2025 Direct
transaction BBNX Common Stock Sale $136,180 -6,818 -18% $19.97 31,215 04 Sep 2025 Direct F1, F2
transaction BBNX Common Stock Options Exercise $58,196 +11,411 +37% $5.10 42,626 05 Sep 2025 Direct
transaction BBNX Common Stock Sale $234,657 -11,411 -27% $20.56 31,215 05 Sep 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBNX Employee Stock Option (right to buy) Options Exercise $0 -656 -0.98% $0.000000 66,428 04 Sep 2025 Common Stock 656 $5.10 Direct F4
transaction BBNX Employee Stock Option (right to buy) Options Exercise $0 -4,093 -11% $0.000000 33,136 04 Sep 2025 Common Stock 4,093 $5.10 Direct F5
transaction BBNX Employee Stock Option (right to buy) Options Exercise $0 -11,411 -34% $0.000000 21,725 05 Sep 2025 Common Stock 11,411 $5.10 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
F2 The weighted average sale price for the transaction reported was $19.9736 and the range of prices were between $19.43 and $20.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $20.564162 and the range of prices were between $20.29 and $20.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F5 The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.